Summary: This study included 15 patients with newly
diagnosed prostate cancer with an average age of 71 years (62-85 years). The
patients received Ukrain at a total dose of 100 mg (10 mg intravenously every
second day, 10 injections altogether). After two to three injections of Ukrain,
all the patients noted considerable subjective improvements in their state.
Ukrain increased the amount of total T-lymphocytes, including "active" T-lymphocytes,
decreased the content of T-suppressors and increased that of T helpers, correspondingly
raising the T-helper/T-suppressor ratio. Our results undoubtedly indicate the
efficacy of Ukrain in the treatment of prostate cancer.